Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-06-29

Clinical Trial Update: Staccato Loxapine in Agitated Patients With Bipolar Disorder [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of Staccato Loxapine for agitation in Bipolar I Disorder has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Staccato Loxapine (loxapine)

Snippet

Sponsor: Alexza Pharmaceuticals, Inc. | Conditions: Bipolar I Disorder | Phase 3 | Status: COMPLETED | Results posted: 2017-06-29